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1. Introduction 
The blood-brain barrier is altered in epilepsy. This includes altered expression of 
transporters and metabolic enzymes as well as barrier leakage that have been linked to 
antiepileptic drug resistance and seizure genesis, respectively. Here we highlight current 
understanding of these pathological changes. Three critical components of barrier function - 
1) tight junctions, 2) metabolising enzymes and 3) transporter proteins - are introduced and 
we describe how they are changed in epilepsy and affected by epilepsy treatment. Recent 
efforts in blood-brain barrier research to overcome drug-resistant epilepsy are also 
discussed.  
2. The blood-brain barrier 
The History of Blood-Brain Barrier Discovery. First experiments contributing to the 
discovery of the blood-brain barrier were performed by Paul Ehrlich in 1885 (Figure 1). 
Ehrlich observed that water-soluble “vital dyes” injected into the blood of rats did not stain 
the brain (Ehrlich, 1885). In 1900, Lewandowsky made similar observations and coined the 
term “blood-brain barrier” (“Bluthirnschranke”) to explain this phenomenon 
(Lewandowsky, 1900). Ehrlich’s student, Edwin Goldmann, injected the same dyes Ehrlich 
had used into the subarachnoid space, and found the opposite: intense staining of the brain 
but no staining of peripheral tissues (Goldmann, 1909; 1913). Goldmann concluded that a 
barrier had to exist between the brain and the periphery, thus the concept of a vascular 
barrier was born. In 1923, Spatz postulated that the brain capillary endothelium had to be 
the structure responsible for barrier function, which initiated a debate that lasted for 
decades (Spatz, 1933). It was Reese and Karnovsky, and Brightman and Reese who solved 
the mystery of the blood-brain barrier in the late 1960s. Using electron microscopy, they 
discovered that tight junctions connect adjacent capillary endothelial cells and seal the 
intercellular space (Brightman & Reese, 1969; Reese & Karnovsky, 1967). With this, the 
molecular structure responsible for barrier function was identified and the barrier was 
localized to the brain capillary endothelium. 
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Fig. 1. Evolution of Blood-Brain Barrier Methodology/History 
The History of the Blood-Brain Barrier in Epilepsy. In the 1930s, Aird and Cobb 
discovered that brain uptake of “vital dyes” was increased in epileptic mice. Based on their 
observation, they suggested that the brain vasculature may be a barrier between the central 
nervous system (CNS) and the periphery and that altered brain vascular permeability may 
be a factor contributing to epilepsy (Aird, 1939; Cobb et al., 1938). In the mid 1950s, Bercel 
used diuretics in patients to increase brain uptake of antiepileptic drugs (AEDs (Bercel, 
1955)). Co-administration with diuretics reduced AED doses below toxic levels in ten of ten 
patients and in seven of these ten patients seizure control was improved (Bercel, 1955). 
Nemeroff and Crisley made a critical discovery in 1975 when they found that glutamate is 
involved in seizure induction and increases cerebrovascular permeability in rats (Nemeroff 
& Crisley, 1975). Further, blood-brain barrier dysfunction was shown to go along with an 
increase in blood pressure and cerebral vasodilation during seizures (Bolwig et al., 1977; 
Petito et al., 1977). In 1989, Clarke and Gabrielsen demonstrated seizure-induced blood-
brain barrier leakage in humans using computed tomography (Clarke & Gabrielsen, 1989). 
In 1995, Tishler et al. made the observation that mRNA of MDR1 (ABCB1), the gene 
encoding the efflux transporter P-glycoprotein (P-gp) is increased at the blood-brain barrier 
of patients with drug-resistant epilepsy (Tishler et al., 1995). This was a critical finding 
because P-gp acts as a “gatekeeper” that limits therapeutic drugs from crossing the blood-
brain barrier and from entering the brain (Miller et al., 2008). Research in this field initially 
focused on P-gp, but other transporters such as multidrug resistance proteins (MRPs) and 
breast cancer resistance protein (BCRP) are also increased in epilepsy animal models or 
patients (Awasthi et al., 2005; Dombrowski et al., 2001; Sisodiya et al., 2006; Van Vliet et al., 
2005). 
Today, the role of some of these transporters in epilepsy is still unclear. It has been 
discussed that P-gp could be involved in seizure generation (Marchi et al., 2004) and that 
multiple transporters may act in concert to limit brain uptake of a broad range of AEDs 
(Lazarowski et al., 2007). Recent studies show that AED-metabolizing enzymes such as 
cytochromes (CYP) 3A4, 2C8, and glutathione sulfotransferase (GST) μ and π are also 
upregulated in the brain of epileptic patients forming a metabolic barrier that contributes to 
AED resistance (Ghosh et al., 2010; Shang et al., 2008; Ueda et al., 2007). 
2.1 Blood-brain barrier anatomy 
Numbers and Facts. The blood-brain barrier is a network of brain capillaries (microvessels). 
With a diameter of 3-7 μm, brain capillaries are the smallest vessels of the vascular system 
(Figure 2A) (Rodriguez-Baeza et al., 2003). The microvasculature in the human brain is 
comprised of about 100 billion capillaries forming a highly branched vascular network 
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(Zlokovic & Apuzzo, 1998). Due to the high capillary density in the brain, capillaries are 
about 40 μm apart from each other, a distance short enough for small molecules to diffuse 
within 1 second (Rodriguez-Baeza et al., 2003). This ensures that every neuron (about 100 
billion in human brain) is in contact with and perfused by its own capillary, which allows 
efficient nutrient and oxygen supply. Despite the huge number of 100 billion brain 
capillaries, the total capillary lumen occupies only about 1% of total brain volume, or about 
12-15 ml in an adult human brain of about 1,400 ml (Pardridge, 2003b). Thus, at any given 
time, about 8-10% (about 10 ml) of total cerebral blood (about 150 ml) is in the lumen of 
brain capillaries. Not taking the capillary lumen into account, it is estimated that the brain 
capillary endothelium occupies only about 0.1% of total brain volume (~ 1-1.5 ml) 
(Pardridge, 2003b). Lastly, the total length of the capillary network is about 600-650 km in an 
adult human brain with a total surface area of about 20 m2. This makes the blood-brain 
barrier the third largest surface area for drug exchange after intestine and lung (Pardridge, 
2003a). 
 
5 μm
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Fig. 2. (A). DIC image of isolated brain capillary. (B) Neurovascular unit. 
Morphology and Anatomy. Brain capillaries are the next higher level of organisation from 
endothelial cells that are the smallest anatomical unit of microvessels. Brain capillary 
endothelial cells are flat, thin, spindle-shaped, polarized cells. Their apical membrane faces 
the blood (luminal), and their basolateral membrane faces the brain parenchyma (abluminal; 
(Betz et al., 1980)). It is through the basement membrane that brain capillary endothelial cells 
are in contact with pericytes, astrocytes, and neurons (Figure 2B; (Goldstein & Betz, 1983)). 
This 4-cell structure is referred to as “Neurovascular Unit” and is responsible for maintaining 
and regulating blood flow, and for controlling barrier function (Begley, 2004).  
One fundamental characteristic of endothelial barrier function is a complex, multi-protein 
structure called a tight junction, which is unique in the vascular system (Nagy et al., 1984). 
Brain capillary endothelial cells also lack intercellular clefts and have low pinocytotic activity, 
which limits solute exchange between blood and brain. Lastly, to meet the large energy 
demand of ATP-consuming processes like metabolism and active efflux transport, brain 
capillary endothelial cells possess a large number of mitochondria (Goldstein & Betz, 1983). 
2.2 Blood-brain barrier physiology 
Blood-brain barrier functions include CNS protection, and regulation and maintenance of 
CNS homeostasis. Three components determine barrier function: 1. Tight Junctions, 2. 
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Transporters and 3. Metabolising Enzymes. The following paragraphs describe these 
components in more detail. 
1. Tight Junctions 
Tight junctions are cell-cell contacts that seal the intercellular space between adjacent 
endothelial cells, thereby creating a non-fenestrated endothelium and limiting hydrophilic 
molecules from paracellular diffusion (Nag, 2003). Tight junctions are multi-protein 
complexes composed of transmembrane proteins like occludins, claudins, e-cadherins and 
junctional adhesion molecules as well as adaptor and regulatory proteins (Matter & Balda, 
2003a; Vorbrodt & Dobrogowska, 2003). Adaptor proteins include zonula occludens 
proteins, cingulin, catenin and membrane-associated guanylate kinase inverted proteins that 
connect junctional transmembrane proteins with cytoskeletal actin filaments (Matter & 
Balda, 2003b). Regulatory proteins include G proteins, atypical protein kinase C isoforms, 
and symplektin that are involved in signalling (Matter & Balda, 2003b; Wolburg & Lippoldt, 
2002). Together, tight junctions guarantee a tight barrier, and thus, protection of the CNS 
(Kniesel & Wolburg, 2000). However, under pathological conditions such as epilepsy, tight 
junctions can be dysfunctional or disrupted, leading to  barrier leakage, impaired neuronal 
function, and brain damage (Huber et al., 2001). 
2. Metabolic Enzymes 
The concept of a “metabolic barrier” is widely accepted but little information is available on 
metabolising enzymes at the blood-brain barrier. Early studies focused on phase I enzymes 
in whole brain tissue but later studies differentiated between different brain cell types. 
Walther et al. showed that CYP P450 enzymes are located in the inner mitochondrial 
membrane of neurons and glia from rat, guinea pig, rabbit, and pig brain. This is in contrast 
to liver, where most CYP isoforms are located at the endoplasmic reticulum (Walther et al., 
1986). Consistent with this, Ghersi-Egea et al. found CYP P450 protein expression in 
mitochondria from rat brain tissue (Ghersi-Egea et al., 1987), and demonstrated CYP activity 
in various brain regions and isolated human microvessels. They found low 1-naphthol-
UDP-glucuronosyltransferase and NADPH-CYP P450 reductase activity, and high GST and 
epoxide hydrolase activity (Ghersi-Egea et al., 1993). The same group also found Cyp P450 
activity in rat brain microvessels (Ghersi-Egea et al., 1994).  
Dauchy et al. used isolated microvessels from resected human brain and found mRNA 
expression of CYP1A1, 1B1, 2B6, 2C8, 2D6, 2E1, 2J2, 2R1, 2S1, and 2U1, and detected 
CYP1B1 by Western blotting (Dauchy et al., 2008). Immunohistological studies by Rieder et 
al. confirmed localisation of CYP1B1 in human brain capillaries (Rieder et al., 2000). In a 
follow up study, Dauchy et al. showed CYP2U1 and CYP2S1 mRNA expression in the 
human cerebral microvascular endothelial cell line hCMEC/D3 (Dauchy et al., 2009). CYPs 
with low mRNA expression included CYP2R1, 2B6, 2E1, 1A1, 2D6, 2C18, 1B1, 2J2, 1A2 and 
2C8. Except for CYP2C18, all CYP genes found in hCMEC/D3 cells were also detected in 
isolated human brain microvessels. A novel CYP P450, Cyp4x1, was identified in 2006 by 
Al-Aznizy et al. in mouse brain (Al-Anizy et al., 2006). Immunohistochemical staining 
showed strong Cyp4x1 protein expression in neurons, choroid plexus epithelial cells, and 
brain microvessel endothelial cells. In 2010, mRNA and protein expression of CYP3A4, the 
most prominent enzyme involved in xenobiotic metabolism in the liver, was found by 
Ghosh et al. in human brain endothelial cells (Ghosh et al., 2010). 
While most blood-brain barrier enzymes have been detected at the mRNA level, protein 
expression and activity of only few enzymes have been demonstrated. These include 
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gamma-glutamyl transpeptidase (Beuckmann et al., 1995), alkaline phosphatase 
(Beuckmann et al., 1995), aromatic L-amino acid decarboxylase (Betz et al., 1980; Matter & 
Balda, 2003b), the phase I metabolising enzymes CYP1A1 (Filbrandt et al., 2004), CYP1B1 
(Filbrandt et al., 2004), CYP3A4 (Ghosh et al., 2010; Ghosh et al., 2011), and Cyp4x1 (Al-
Anizy et al., 2006), NADPH-CYP P450 reductase (Chat et al., 1998; Ghersi-Egea et al., 1988; 
Minn et al., 1991; Ravindranath et al., 1990), epoxide hydrolase (Ghersi-Egea et al., 1988; 
Minn et al., 1991), and the phase II enzymes, 1-naphthol-UDP-glucuronosyltransferase 
(Ghersi-Egea et al., 1988) and GSTμ (Shang et al., 2008), and GSTπ (Bauer et al., 2008; Shang 
et al., 2008). 
The presence of these enzymes in the brain microvasculature indicates the existence of a 
metabolic barrier. However, more studies are needed to better define the role metabolising 
enzymes play at the blood-brain barrier under physiological and pathophysiological 
conditions and whether these enzymes can indeed limit AED delivery to the brain. 
3. Transporters 
The blood-brain barrier is an active, dynamic and selective interface that responds to signals 
from both the periphery and brain. Key components of barrier function include influx and 
efflux transporters that are responsible for brain homeostasis, nutrient supply, and 
protection of the brain from endogenous and exogenous toxins. 
Influx transporters that maintain CNS homeostasis and nutrient supply include A-and N-
system amino acid transporters (Betz et al., 1980; O'kane & Hawkins, 2003), excitatory amino 
acid carriers 1, 2, and 3 (O'kane & Hawkins, 2003; O'kane et al., 1999), 
alanine/serine/cysteine/threonine (ASCT) transporters for neutral amino acids (Boado et al., 
2004; Tayarani et al., 1987), glucose transporters GLUT1 and GLUT3/14 (Pardridge, 1991; 
Simpson et al., 2007), monocarboxylate transporters MCT1 and MCT8 (Braun et al., 2011; Ito et 
al., 2011; Simpson et al., 2007), and the equilibrative nucleoside transporter ENT1 (Kitano et al., 
2002), as well as Na+-K+-ATPase (Betz et al., 1980). These transporters belong to the solute 
carrier (SLC) superfamily. Prominent SLC transporters that have been detected at the blood-
brain barrier also include the organic anion transporter Oat3, organic anion transporting 
polypeptides Oatp1a4, 1b1, 1c1, 2b1, 14, and organic cation transporters OCT1, OCT2 (Ito et al., 
2011; Lin et al., 2010). Of these SLCs, Oat3, Oatps, and Octs are involved in drug transport. 
However, it is currently not known if these SLC transporters can handle AEDs. 
An interesting blood-brain barrier transporter is the large neutral amino acid transporter 
LAT that transports the amino acids valine, leucine, isoleucine, tryptophan, and tyrosine. 
LAT1 mediates brain uptake of L-DOPA that is used in Parkinson’s disease (Del Amo et al., 
2008). LAT1 has also been reported to transport the AEDs gabapentin and pregabalin across 
the blood-brain barrier into the brain (Del Amo et al., 2008; Liu et al., 2008; Su et al., 1995). 
Whether LATs are affected in epilepsy is unknown. 
In total, 21 transporters have been detected at the protein level in brain capillaries and brain 
capillary endothelial cells from various species by immunohistochemistry, Western blotting, 
or quantitative LC/MS/MS (Kamiie et al., 2008; Neuwelt et al., 2011). Seven of these 
transporters belong to the ABC (ATP-binding cassette) transporter family and include P-
glycoprotein (P-gp, MDR1, ABCB1), the multidrug resistance proteins 1, 2, 3, 4, and 5 
(MRPs, ABCC1-5) and breast cancer resistance protein (BCRP, ABCG2). These transporters 
are ATP-driven and mainly located at the luminal membrane of the brain capillary 
endothelium (Mrp1 and Mrp4 are also in the abluminal membrane). This “first line of 
defence” protects the brain from neurotoxicants and limits CNS drugs from entering the 
brain, and thus, is an obstacle for CNS pharmacotherapy.  
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Together, transporters ensure proper CNS nutrient supply and mediate efflux of metabolic 
wastes from the brain, thus, helping maintain CNS homeostasis. The following section 
describes the role of transporters, metabolic enzymes, and barrier leakage in epilepsy. 
3. Blood-brain barrier function in epilepsy 
Epilepsy affects more than 60 million people worldwide. The majority of patients respond to 
treatment with AEDs, but up to 40% of patients are drug-resistant (Kwan & Brodie, 2003; 
Loscher & Potschka, 2005). Patients with AED resistance suffer from uncontrolled seizures, 
which elevates their risk of brain damage and mortality (Sperling et al., 1999). These patients 
experience a low quality of life and, despite advances in pharmacotherapy and 
neurosurgery, drug-resistant epilepsy remains a major clinical problem (Devinsky, 1999).  
Evidence indicates that the blood-brain barrier is altered in patients with epilepsy. Changes 
in the brain capillary endothelium include upregulation of efflux transporters and metabolic 
enzymes as well as barrier leakage that have been linked to AED resistance and seizure 
genesis (Bauer et al., 2008; Ghosh et al., 2010; Marchi et al., 2007). The following section 
describes the role of transporters, metabolic enzymes, and barrier leakage in epilepsy. 
3.1 Transporters in epilepsy 
One factor underlying AED resistance is, at least in part, seizure-induced over-expression of 
drug efflux transporters at the blood-brain barrier (Bauer et al., 2008). Some of these 
transporters, such as P-gp, Mrp2, and BCRP have been implicated with AED resistance. The 
first evidence for involvement of efflux transporters in epilepsy goes back to studies by 
Tishler and co-workers in 1995. These researchers observed increased P-gp mRNA in the 
brain and protein expression in the capillary endothelium of patients with drug-resistant 
epilepsy (Tishler et al., 1995). The findings by Tishler et al. were confirmed by other groups 
(Dombrowski et al., 2001; Lazarowski et al., 1999; Sisodiya et al., 2002) and it was suggested 
that this phenomenon could prevent AEDs from entering the brain and cause AED 
resistance. However, studies in cell lines of non-brain endothelial origin showed that some 
AEDs such as vigabatrin, gabapentin, phenobarbitone, lamotrigine, carbamazepine, and 
phenytoin are not, or are only weak, P-gp substrates, questioning whether P-gp could be the 
primary reason for AED resistance (Crowe & Teoh, 2006; Maines et al., 2005; Owen et al., 
2001; Weiss et al., 2003). In contrast, Cucullo et al., compared phenytoin permeation in brain 
capillary endothelial cells from drug-resistant epileptic human brain tissue with that of 
commercially available human brain microvascular endothelial cells (Cucullo et al., 2007). 
They demonstrated that phenytoin permeation was 10-fold lower in endothelial cells from 
AED-resistant patients compared to purchased human endothelial cells. Although this 
comparison is flawed, inhibiting P-gp increased phenytoin permeation in the AED-resistant 
cells. Moreover, recent in vivo data, including our own studies, demonstrate that P-gp does 
limit AEDs from entering the brain (Brandt et al., 2006; Liu et al., 2007; Van Vliet et al., 2007). 
Using a drug-resistant epilepsy rat model, Potschka et al. showed that animals not 
responding to phenytoin exhibited 2-fold higher P-gp expression levels in brain capillaries 
compared to animals responding to treatment (Potschka et al., 2004). van Vliet et al. 
demonstrated that inhibiting P-gp counteracted phenytoin resistance, which reduced 
seizure occurrence in rats (Van Vliet et al., 2006). Marchi et al. supported these findings 
showing that patients with high blood-brain barrier P-gp expression had low brain levels of 
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oxcarbazepine (Marchi et al., 2005). These studies demonstrate that, in drug-resistant 
epilepsy, certain, but not all AEDs have restricted access to the brain due to increased blood-
brain barrier P-gp, and that modulation of P-gp can enhance brain distribution of some 
AEDs such as phenytoin (Potschka & Loscher, 2001; Van Vliet et al., 2006; Van Vliet et al., 
2007). 
In addition to P-gp, data indicate that BCRP plays a significant role in drug efflux at the 
blood-brain barrier. Recent studies show that both transporters, P-gp and BCRP, “team up” 
and work together to limit chemotherapeutic drugs from permeating across the blood-brain 
barrier and penetrating into the brain (Chen et al., 2009; De Vries et al., 2007). However, little 
information is available on the extent to which BCRP contributes to AED resistance and if P-
gp and BCRP work in concert in AED efflux from the brain. Some studies found no 
upregulation of BCRP in human epileptogenic brain tissue and no evidence for BCRP-
mediated AED transport in vitro (Cerveny et al., 2006; Sisodiya et al., 2003), but other studies 
reported upregulation of BCRP expression in the microvasculature of epileptogenic brain 
tumors (Aronica et al., 2005; Vogelgesang et al., 2004) and in chronic epilepsy animal models 
(Van Vliet et al., 2005). More studies are needed to unequivocally clarify the role of BCRP, 
especially in conjunction with P-gp, in AED-resistant epilepsy.  
Only little information is available on the multidrug resistance proteins (Mrps) in epilepsy. 
van Vliet et al. used the pilocarpine status epilepticus model in rats and found by 
immunohistochemistry and Western blotting that Mrp1 and Mrp2 protein expression was 
upregulated in astrocytes within several limbic structures including the hippocampus (Van 
Vliet et al., 2005). These findings were confirmed by Hoffmann et al., who also 
demonstrated Mrp2 upregulation in brain capillaries by immunohistochemistry following 
pilocarpine-induced status epilepticus (Hoffmann et al., 2006). In control rats, Mrp2 was 
barely detectable in the brain capillary endothelium, but in status epilepticus rats, Mrp2 
staining was evident in brain capillary endothelial cells. MRP2 has also been found to be 
over-expressed in sclerotic hippocampal tissue of AED-resistant patients with mesial 
temporal lobe epilepsy (Aronica et al., 2004). In the same patient population, MRP1 
expression was upregulated in glial endfoot processes around cerebral blood vessels. 
Observations of chronic epileptic rats showed that protein levels of Mrp1 and Mrp2 were 
also upregulated in blood vessels and this over-expression correlated with seizure frequency 
and reduced brain uptake of phenytoin (Van Vliet et al., 2005). However, phenytoin brain 
uptake was enhanced by the MRP inhibitor probenecid. While upregulation of mRNA was 
observed for Mrp1, 5, and 6, increased protein expression was only found for MRP1 and 2 in 
isolated capillary endothelial cells from patients with drug-resistant epilepsy (Dombrowski 
et al., 2001; Kubota et al., 2006). A time-course study revealed that 6-24 h after onset of a 
pilocarpine-induced status epilepticus in rats, mRNA of P-gp, Mrp1, and Mrp5 was 
decreased in hippocampus, amygdala, and the piriform cotex. This initial decrease in 
mRNA levels was followed by a 24h period of normal mRNA expression and then increased 
mRNA levels about 4 days after status epilepticus (Kuteykin-Teplyakov et al., 2009). These 
findings are in contrast to an earlier study where P-gp mRNA levels in mouse hippocampus 
were increased by 85% 3-24 h after kainic acid-induced limbic seizures, but returned to 
control levels after 72 h (Rizzi et al., 2002). Treatment with AEDs for 7 days did not change 
P-gp mRNA expression (Rizzi et al., 2002). In the same study, the authors also used rats with 
spontaneous recurrent seizures 3 months after electrically induced status epilepticus. P-gp 
mRNA levels were increased 1.8- and 5-fold in the hippocampus and entorhinal cortex, 
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respectively. Thus, changes in P-gp mRNA levels occur after both acute and chronic 
epileptic activity. The same authors (Rizzi et al., 2002) also used microdialysis and 
demonstrated that AED brain levels were significantly reduced. While a direct connection 
between blood-brain barrier P-gp levels and AED brain levels was not shown, it was 
concluded that seizure-induced changes in P-gp could contribute to AED resistance in 
epilepsy. Note that none of these studies provided data on transporter protein expression or 
activity. 
3.1.1 Transporter inhibition 
The discovery that drug efflux transporters are upregulated at the blood-brain barrier in 
AED-resistant patients suggested that transporter inhibition could overcome AED resistance 
in epilepsy. This notion was encouraged by studies that showed enhanced brain uptake of 
AEDs when co-administered with transporter inhibitors. Using verapamil and probenecid, 
Potschka et al. used microdialysis and demonstrated in healthy rats that P-gp and Mrp limit 
carbamazepine brain uptake (Potschka & Loscher, 2001). A follow-up study showed that 
administration of the metabolic inhibitor sodium cyanide and the P-gp inhibitors verapamil 
and PSC833 into the frontal cortex significantly increased extracellular fluid concentrations 
of phenytoin. This indicated that P-gp limits phenytoin distribution into the brain under 
physiological conditions (Potschka & Loscher, 2001). Similar observations were made with 
phenobarbital, lamotrigine, and felbamate (Potschka et al., 2002). Verapamil has also been 
used in case studies with AED-resistant patients (Iannetti et al., 2005; Summers et al., 2004). 
For example, the status epilepticus in an 11-year old boy who was first unresponsive to 
conventional AEDs disappeared after administration of verapamil i.v. (Iannetti et al., 2005). 
However, this anticonvulsive response could have been due to verapamil directly blocking 
neuronal calcium channels instead of inhibiting P-gp at the blood-brain barrier.  
In 2005, tariquidar (XR9576), a non-competitive P-gp inhibitor was first used to block P-gp 
function. (Martin et al., 1999; Mistry et al., 2001). Tariquidar has a good oral bioavailability, 
long duration of action and low potential for toxic side effects, all of which make this a 
favourable P-gp inhibitor. For example, van Vliet et al. demonstrated that inhibiting P-gp 
with tariquidar significantly reduced seizure duration, frequency and severity, which 
improved phenytoin efficacy in a rat model for temporal lobe epilepsy. This suggested that 
combination of AEDs with a transporter inhibitor may be a promising therapeutic strategy 
for AED-resistant patients (Van Vliet et al., 2006). The same researchers also found that P-gp 
over-expression in the temporal hippocampus and parahippocampal cortex of chronic 
epileptic rats reduced phenytoin levels by about 30% in these brain regions. Treating 
animals with tariquidar significantly increased phenytoin brain levels in regions with over-
expressed P-gp (Van Vliet et al., 2007). Another group found that tariquidar restored the 
anticonvulsive activity of phenobarbital in drug-resistant rats (Brandt et al., 2006). These 
animal studies demonstrate that transporter inhibition increases AED blood and brain levels 
and improves seizure control. 
Encouraged by animal studies and case reports that suggested transporter inhibition can be 
used to overcome AED resistance in epilepsy, clinical trials employing P-gp inhibitors were 
initiated. Currently, two trials using carvediol and verapamil to inhibit P-gp in AED 
refractory patients are ongoing (www.clinicaltrials.gov, #NCT00524134, #NCT01126307). 
However, while both carvedilol and verapamil are FDA-approved and readily available, 
neither drug is a highly specific nor potent P-gp inhibitor (Arboix et al., 1997; Takara et al., 
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2004). In addition, to effectively inhibit over-expressed P-gp, high inhibitor plasma 
concentrations will be needed, which carries the risk of drug-drug interactions and toxic 
side effects (Pennock et al., 1991). In a recent study, add-on treatment with verapamil to 
improve seizure control in dogs with phenobarbital-resistant epilepsy had to be 
discontinued due to detrimental effects (Jambroszyk et al., 2011). Thus, since potent and 
specific inhibitors that can be safely given to patients are currently not available, transporter 
inhibition does not seem to be a viable treatment option in drug-resistant epilepsy at this 
point in time. 
3.1.2 Modulation of transporter regulation 
Targeting signalling pathways that regulate drug efflux transporters is another strategy to 
overcome transporter-mediated AED resistance. The advantages of this approach are three-
fold. First, modulating transporter regulation to increase AED brain delivery may allow fine 
tuning of the transporter. For example, modulating the molecular switches of a transporter 
may allow turning it off for a short, controlled period of time to deliver drugs into the brain, 
after which it can be turned on again. Second, preventing or blocking seizure-induced 
upregulation of transporters may normalise transporter expression and functional activity, 
and thus, prevent or block development of transporter-mediated AED resistance. Third, 
since transporter upregulation in epilepsy has been linked to increased seizure occurrence, 
prevention of transporter upregulation holds the promise of better seizure control. Thus, 
mapping the signalling pathways involved in efflux transporter upregulation at the blood-
brain barrier in epilepsy can help identify new targets that may potentially be used to 
overcome transporter-mediated AED resistance and improve seizure treatment. 
Several signalling pathways have been identified that regulate P-gp, BCRP, and Mrp2 at the 
blood-brain barrier. For BCRP, the most recent signalling mechanisms include Nrf2, NfkB, 
COX-2, Pim-1 kinase, and the nuclear receptors CAR and AhR (Kalalinia et al., 2011; Singh 
et al., 2010; Tan et al., 2010; Wang et al., 2010). Of those, CAR and AhR have been shown to 
upregulate BCRP at the blood-brain barrier (Tan et al., 2010; Wang et al., 2010), which is the 
opposite of what one would want to improve AED delivery into the brain. Whether 
targeting any of the other pathways could be used as a therapeutic strategy in AED-resistant 
epilepsy is unknown and remains to be determined. Mrp2 is also regulated through nuclear 
receptors (PXR, FXR, CAR; (Bauer et al., 2008; Kast et al., 2002)), but the signalling that 
upregulates Mrp2 in epilepsy is unknown. 
Most information on transporter regulation is available for P-gp, where signalling pathways 
have been shown to be present in various tissues (liver, kidney, intestine; (Ho & Piquette-
Miller, 2006; Nawa et al., 2010; Thevenod et al., 2000). They also involve various signalling 
molecules: inflammatory mediators including TNF-ǂ, ET-1, IL1-ǃ, IL-6, NO; COX-2 (Dixit et 
al., 2005; Goralski et al., 2003; Nawa et al., 2010; Patel et al., 2002; Poller et al., 2010; Sukhai et 
al., 2001; Von Wedel-Parlow et al., 2009), nuclear receptors PXR, CAR, AhR, and GR (Bauer 
et al., 2004; Bauer et al., 2007; Geick et al., 2001; Narang et al., 2008; Wang et al., 2011; Wang 
et al., 2010), protein kinase C (Bauer et al., 2007; Chambers et al., 1990a; Chambers et al., 
1990b; Hartz et al., 2004; Miller et al., 1998; Rigor et al., 2010), and NFkB (Bauer et al., 2007; 
Bentires-Alj et al., 2003; Kim et al., 2011; Liu et al., 2008; Thevenod et al., 2000; Yu et al., 
2008). These pathways have been found in several diseases including Alzheimer’s disease, 
HIV, and diabetes (Hartz et al., 2010; Hayashi et al., 2006; Nawa et al., 2010).  
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One pathway that involves glutamate signalling through the NMDA receptor (NMDAR) 
followed by cyclooxygenase -2 (COX-2) and prostaglandin E receptor 1 (EP1) activation 
seems to be critical for seizure-induced upregulation of P-gp (Figure 3, (Bankstahl et al., 
2008; Bauer et al., 2008; Pekcec et al., 2009; Zhu & Liu, 2004)). During seizures, neurons 
release high amounts of the excitatory neurotransmitter glutamate, which can reach 
interstitial brain concentrations of 10-100 μM for a short period of time (Ronne-Engstrom et 
al., 1992; Ueda & Tsuru, 1995). Zhu and Liu were the first to connect glutamate with P-gp 
upregulation at the blood-brain barrier. They found that glutamate increased P-gp 
expression and activity in rat brain microvessel endothelial cells and suggested that 
activation of the NMDAR plays a critical role in glutamate-mediated P-gp upregulation 
(Zhu & Liu, 2004). Consistent with this, Bauer et al. demonstrated that exposing isolated rat 
and mouse brain capillaries to glutamate increased P-gp expression and activity (Bauer et 
al., 2008). It was shown that glutamate signalling through NMDAR and COX-2 upregulates 
blood-brain barrier P-gp, and that COX inhibition prevented P-gp upregulation suggesting 
that AED brain uptake can be enhanced by COX inhibition. Bankstahl et al. confirmed 
glutamate involvement in seizure-induced P-gp over-expression and that blocking NMDAR 
prevents P-gp upregulation and neuronal damage in vivo (Bankstahl et al., 2008). Another 
study showed that pre-treatment with celecoxib, a specific COX-2 inhibitor, prevented 
seizure-induced P-gp upregulation in rat brain capillaries (Zibell et al., 2009), and yet 
another study demonstrated that pre-treatment with celecoxib for 6 days followed by 
administration of phenobarbital for 16 days reduced the frequency of spontaneous recurrent 
seizures and restored the anticonvulsant effect of phenobarbital in AED-resistant epileptic 
rats (Schlichtiger et al., 2010). van Vliet et al. evaluated the use of the COX-2 inhibitors SC-
58236 and NS-398 in rats with recurrent spontaneous seizures. They found that 2-week 
treatment with these COX-2 inhibitors prevented P-gp upregulation and enhanced 
phenytoin brain uptake in chronic epileptic rats (Van Vliet et al., 2010). While these studies 
are promising, COX-2 inhibitors bear the risk of severe cardio- and cerebrovascular side 
effects (Mukherjee, 2001; Stollberger & Finsterer, 2003). In addition, it has been 
demonstrated that COX-2 inhibition can lead to increased seizure frequency and mortality 
in epileptic rats (Holtman et al., 2010). Thus, although COX-2 inhibition may reduce AED 
resistance in animal models, it may not be a valid target in the clinic over the long term. 
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Fig. 3. Glutamate – NMDAR1 – COX-2 – EP1 Signaling Pathway 
www.intechopen.com
 The Blood-Brain Barrier in Epilepsy 
 
33 
Another signalling protein involved in glutamate-mediated P-gp upregulation at the blood-
brain barrier is the EP1 receptor. EP1 is activated by prostaglandin E2, the main product of 
COX-2, and was tested as potential target to prevent transporter upregulation in epilepsy. 
Pekcec et al. found that EP1 is a key signalling protein in the pathway that drives P-gp 
upregulation during seizures (Pekcec et al., 2009). Studies using the EP1 inhibitors SC-51089 
and misoprostol showed that SC-51089 decreased seizure severity in rats when given prior 
to electrical kindling, but it also prolonged seizure duration at higher doses, whereas 
misoprostol decreased duration of motor seizure activity (Fischborn et al., 2010).  
Together, these studies show that glutamate released during seizures mediates P-gp 
upregulation through NMDAR, COX-2, and EP1 and that these signalling proteins could 
potentially be used as therapeutic targets to reduce AED-resistance. Whether this pathway 
also signals upregulation of other blood-brain barrier proteins is unknown at this time. 
3.2 The metabolic blood-brain barrier 
Xenobiotic metabolism is a 3-phase process during which low polar molecules (e.g., drugs) 
are enzymatically converted to polar molecules that are then excreted from the body mostly 
through bile, faeces, or urine. Most chemicals are pharmacologically or toxicologically 
inactivated during metabolism, only some are transformed into active metabolites. The liver 
is recognized as the main site of biotransformation, but extrahepatic tissues such as the 
kidney, lung, intestine, skin, and brain also contribute to drug metabolism.  
The processes involved in the biotransformation of drugs are classified into phase I 
(functionalisation) and phase II (conjugation) reactions that are followed by phase III 
excretion of the metabolite (Figure 4). Substrates of phase I enzymes are in general lipophilic 
and undergo functionalisation reactions such as monooxygenation, dealkylation, reduction, 
aromatisation, or hydrolysis. The modified molecules are substrates for phase II enzymes, 
which conjugate the functional group with a polar compound, such as an amino acid, 
sulphate, glutathione, or a sugar (Minn et al., 1991). In the last phase III step, functionalised 
and conjugated xenobiotics are excreted from cells by efflux transporters. 
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Fig. 4. Schematic of 3-phase drug metabolism and excretion 
Most CNS drugs, including AEDs, have to cross the blood-brain barrier and penetrate into 
the brain parenchyma to reach their target sites. En passage across the barrier and within the 
brain, drugs can undergo inactivation and elimination comparable to hepatic drug 
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metabolism. In the brain, the following phase I enzymes have been identified: monoamine 
oxidases, CYP P450, NADPH-CYP P450 reductase, and epoxide hydrolases (Chat et al., 1998; 
Dutheil et al., 2010; Ghersi-Egea et al., 1998; Ghersi-Egea et al., 1988; Ghersi-Egea et al., 1993; 
Minn et al., 1991; Ravindranath et al., 1990). Phase II enzymes identified in the brain include 
UDP-glucuronosyltransferase (UGT), phenol sulfotransferase (PST), and GST (Dutheil et al., 
2010; Ghersi-Egea et al., 1998; Ghersi-Egea et al., 1988; Ghersi-Egea et al., 1993; Minn et al., 
1991). Several phase I and II enzymes have been found in the brain capillary endothelium, 
where they possibly form a metabolic barrier for drugs en route into the brain  (Dutheil et 
al., 2010; Ghersi-Egea et al., 1998; Ghersi-Egea et al., 1993; Minn et al., 1991; Stamatovic et al., 
2008). Several reports on metabolism-coupled efflux transport (phase III) suggest that 
biotransformation of drugs and efflux of the metabolites are part of barrier function. 
Together, the rodent and human brain, including brain microvessels forming the blood-
brain barrier, express enzymes and transporters that are part of the detoxification pathways 
that affect metabolism of therapeutic drugs. In addition, AED elimination by coupling of 
two important biological processes – metabolism and efflux transport - could contribute to 
AED resistance and intractable epilepsy. 
3.2.1 Metabolism of AEDs and the metabolic barrier in epilepsy 
Phase I. CYP P450 enzymes are responsible for most phase I metabolic reactions and have 
the greatest impact on the biotransformation of therapeutic drugs. CYPs form a large and 
functionally diverse superfamily of enzymes that are found throughout various species 
ranging from bacteria to humans. In humans, the majority of CYPs are expressed along the 
inner plasma membranes of mitochondria and the endoplasmic reticulum. Although a 
distinct group of CYPs (CYP11A1, 11B1, 11B2, 17A1, 21A2) is involved in steroid hormone 
synthesis in humans (Hrycay & Bandiera, 2009), most CYP enzymes contribute primarily to 
the elimination of endogenous and exogenous substrates through oxidation to enhance their 
excretion from the body. By-in-large, CYP-mediated metabolism occurs in the liver and 
contributes to the “first pass effect” of orally administered drugs. In the liver, several CYPs 
exist as allelic or genetic variants and such CYP polymorphisms have been shown to 
influence the plasma concentration of some AEDs. CYPs are also expressed in the kidney 
and renal excretion is an important elimination route, particularly for most novel AEDs. 
With regard to epilepsy it is noteworthy that many AEDs are metabolised by CYPs (Table 
1). CYP2C9 and CYP2C19 are the two major enzymes involved in AED metabolism 
including diazepam, phenobarbital, phenytoin, and valproic acid (Table 1; (Klotz, 2007)). 
Several studies demonstrated differences in the biotransformation of these AEDs depending 
on the underlying CYP genotype. For example: phenytoin metabolism depends on the allelic 
composition of the gene encoding for CYP2C19 and CYP2C9. Several mutated alleles of 
these genes are known. Thus, based on genotype, poor phenytoin metabolisers can be 
distinguished from phenytoin hypermetabolisers and their frequency distributions vary 
between different ethnic populations (Klotz, 2007). 
Regarding CYPs in the brain, in vitro and in vivo functional expression of CYPs has been 
detected in various CNS cell types from different species. CYP expression in distinct CNS 
cell populations is variable but can be as high as in the liver (Bhagwat et al., 2000). 
Importantly, it has been shown that CYPs are functionally active at the blood-brain barrier 
(Dutheil et al., 2010).  
www.intechopen.com
 The Blood-Brain Barrier in Epilepsy 
 
35 
DRUG  ENZYME/PATHWAY  
Carbamazepine CYP3A4, mEH1 for carbamazepinee-10, 11-epoxide  
Ethosuxemid CYP3A4?, 10-20% renal 
Phenobarbital CYP2C19, hydroxylation, glucuronidation, 25% renal  
Phenytoin CYP2C9, CYP2C19 
Valpoate CYP2C9, glucuronidation, oxidation 
Diazepam CYP2C19, CYP3A4 
Felbamate 40-60% renal, hydroxylation, glucuronidation 
Gabapentin Renal 
Lamotrogine Glucuronidation, 8% renal 
Levetirazepam 66% renal, hydrolyse 
Oxcabazepine Reduction to active metabolite that is glucuronidated  
Pregabalin 98% renal 
Tiagabine CYP3A4, 25% renal 
Topiramate 60-80% renal, oxidation, hydrolysis, glucuronidation  
Vigabatrin 60-80% renal 
Zonizamide CYP3A4, N-acetylation, glucuronidation, 30% renal  
Table 1. Antiepileptic drugs and their route of biotransfomation (modified from Klotz, 2007) 
In the human brain, 20 CYP isoforms have been identified so far: CYP1A1, 1A2, 1B1, 2B6, 
2C8, 2D6, 2E1, 3A4, 3A5, 8A1, 11A1, 11B1, 11B2, 17A1, 19A1, 21A2, 26A1, 26B1, 27B1, and 
46A1 (Dutheil et al., 2010). The exact expression pattern within the CNS depends on the 
particular CYP and greatly varies between different brain cells. In a recent study, CYP 
mRNA expression levels were measured in a human brain microvessel cell line and in 
human microvessels isolated from surgically removed brain tissue from epileptic patients or 
patients with brain tumours (Dauchy et al., 2008). The authors found mRNA expression of 
CYP2U1, CYP2S1, CYP2R1, CYP2B6, CYP2E1, CYP1A1, CYP2D6, CYP1B1, CYP2J2, 
CYP1A2, and CYP2C8. In another study, Gosh et al. used commercially available human 
microvascular cerebral endothelial cells and found mRNA expression of CYP1A1, 1B1, 2A6, 
2B6 2C, 2C9, 2E1, 2J2, 3A4, 4A11, 11b, CYP3A5, 4B1, C1, 21A, and 51A1 (Ghosh et al., 2010). 
The cells that were used for this study originated from surgically resected brain specimens 
of drug-resistant epileptic patients, brain specimens resected from aneurism domes, 
commercially available human microvascular cerebral endothelial cells (used as control), 
and from human umbilical vein endothelial cells (used as control). mRNA expression from 
11 of the 16 CYPs was increased in endothelial cells from epileptic tissue compared to 
microvascular cerebral endothelial cells. Although this comparison may be flawed due to 
the different nature of these cells, mRNA expression in endothelial cells from drug-resistant 
epileptic patients was not different compared to brain specimens resected from aneurism 
domes without seizures (Ghosh et al., 2010). This result argues against a seizure effect on the 
regulation of blood-brain barrier CYPs. However, it is clear from these findings that more 
detailed and accurate studies with appropriate controls are needed. 
Overall, expression profiles, tissue and cellular distribution, and relative expression of CYP 
enzymes seem to depend on study design and the models used. Therefore, additional 
research is needed to clarify the importance of individual CYPs at the blood-brain barrier 
under both physiological and epileptic conditions. 
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CYP Regulation in the CNS  
Carbamazepine induces CYP3A4 protein and mRNA expression in human brain endothelial 
cells and hepatocytes (Ghosh et al., 2010; Luo et al., 2002). But carbamazepine is metabolized 
by CYP3A4 (, Table 1), and high expression of CYP3A4 protein was found in endothelial 
cells isolated from surgically resected epileptic brain tissue (Ghosh et al., 2011). Neuronal 
CYP3A4 expression has also been demonstrated in brain sections by immunostaining from 
patients with temporal lobe epilepsy, tuberous sclerosis, or cavernous angioma, all of whom 
had intractable epilepsy. In these samples, CYP3A4 was rarely co-localised with the 
astrocytic marker GFAP (Ghosh et al., 2011). Carbamazepine given to cells that derived from 
resected epileptic brain tissue underwent metabolism at an extent similar to what was 
observed in hepatocytes. Thus, increased CYP3A4 expression and metabolic function could 
be characteristic for endothelial cells in epilepsy, which could contribute to AED resistance. 
As mentioned before, AEDs such as carbamazepine act as strong inducers of hepatic and 
blood-brain barrier CYP expression, thereby influencing the pharmacokinetics of other 
drugs. Other AEDs have also been reported to increase CYP expression at the blood-brain 
barrier and exposure of primary rat brain astrocytic cultures to phenytoin increased 
Cyp2c29 levels (Volk et al., 1995). Moreover, phenytoin was metabolised by the microsomal 
fraction of astrocyte cultures and chronic treatment of mice with phenytoin resulted in 
increased levels of phenytoin metabolites in the brain (Volk et al., 1988). These findings 
support the idea of dynamic CYP regulation at the blood-brain barrier by AED exposure. In 
general, regulation of CYPs at the blood-brain barrier could be independent from that in the 
liver. Support for this comes from studies in alcoholics. Levels of CYP2D6 protein were 
elevated in the brains of alcoholics compared to non-alcoholics (Dutheil et al., 2010; Miksys 
& Tyndale, 2004). Particularly high CYP2D6 levels were detected in the putamen, globus 
pallidus, and substantia nigra, but interestingly, CYP2D6 was not elevated in the liver 
(Dutheil et al., 2010). Nuclear receptors that act as transcription factors control regulation of 
CYPs and ABC transporters in the CNS. In the human brain, several nuclear receptors have 
been detected that could control CYP regulation, including AhR, PXR, FXR, CAR, LXRß, 
RXRǂ and ǃ, PPAR-ǂ, -ǅ, and –Ǆ (Dutheil et al., 2009; Nishimura et al., 2004). For example, 
Dauchy et al. showed that the AhR agonist TCDD increased mRNA expression of CYP1A1 
and CYP1B1 in the human cell line hCMEC/D3 (Dauchy et al., 2008). Thus, it is possible that 
nuclear receptors could be involved in the regulation of CYPs at the blood-brain barrier in 
epilepsy (Dauchy et al., 2008; Dauchy et al., 2009; Ghosh et al., 2010). This idea is supported 
by the fact that metabolites of CYP2J2, which is expressed in brain endothelial cells in 
epilepsy, activate the nuclear receptors PPAR-ǂ (NR1C1) and PPAR-Ǆ (NR1C3). Future 
studies are required to address CYP regulation at the blood-brain barrier in health, disease 
(e.g., epilepsy), and during pharmacotherapy (e.g., AED treatment).  
Phase II & III. Metabolism-driven efflux transport, i.e., coupling of phase II and III, has 
been demonstrated in the liver. Analogous findings from studies at the blood-CSF-barrier 
show coupling of metabolism and efflux transport also in the CNS. Using cultured rat 
choroid plexus epithelial cells in vitro, Strazielle and Ghersi-Egea demonstrated the presence 
of a metabolism-driven efflux mechanism for 1-naphthol, a cytotoxic, lipophilic model 
compound (Strazielle & Ghersi-Egea, 1999). The authors showed that UGT metabolised 1-
naphthol in situ into a glucurono-conjugate (phase II) that was excreted by an efflux 
transporter (phase III). In this regard, MRPs have been implicated in cellular export of 
various glutathione, glucuronide, and sulfate conjugates compounds, and several other 
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endogenous and xenobiotic compounds (Gerk & Vore, 2002; Jedlitschky et al., 1996; Loe et 
al., 1996; Oude Elferink & Jansen, 1994). Although Mrp involvement has not directly been 
shown in Strazielle and Ghersi-Egea’s study, Mrp-mediated efflux of the 1-naphthol 
glucurono-conjugate seems likely as the export was sensitive to the Mrp inhibitor 
probenecid. Thus, this study demonstrated the biological relevance of metabolism-driven 
efflux in the brain (Strazielle & Ghersi-Egea, 1999). However, in the human brain, UGT-
mediated metabolism of 1-naphthol is less prominent compared to rat brain, and therefore, 
species differences should be considered (Ghersi-Egea et al., 1993). Activity of another phase 
II enzyme, GST, seems to be more relevant for human metabolism (Ghersi-Egea et al., 1993). 
Metabolism-driven transport was shown for GSTπ and Mrp1 by Leslie et al., who 
demonstrated plasma membrane co-localisation of Mrp1 and GSTπ in H69AR cells and 
found that functional GSTπ was required for Mrp1-mediated transport (Leslie et al., 2004). 
mRNA and protein expression of the GST isoform π has been demonstrated in isolated rat 
and mouse brain capillaries, where GSTπ is predominantly localized in the cytoplasm and 
the luminal plasma membrane of brain capillary endothelial cells, and to a large extent, co-
localises with Mrp2 in the membrane (Bauer et al., 2008). Consistent with regulation by the 
nuclear receptor PXR, GSTπ protein expression increased in membranes from rat brain 
capillaries exposed to PCN or dexamethasone, and in capillary membranes from rats dosed 
with PCN. Immunoblotting of the capillary membrane fraction from hPXR transgenic mice 
dosed with rifampin further showed enhanced GSTπ expression. GSTπ and Mrp2 
upregulation occurred in parallel, suggesting coordinated regulation of phase-II metabolism 
and phase-III efflux, i.e. Mrp2-mediated transport (Bauer et al., 2008). While these studies 
provide first insight into the regulation of both GSTπ and Mrp2 in brain capillaries, direct 
proof of metabolism-coupled efflux transport of chemicals at the blood-brain barrier 
remains to be shown. Thus, metabolism-coupled excretion of CNS drugs, such as AEDs, by 
efflux transporters seems likely, but requires further studies. Such studies would have to 
take into consideration the specific conditions at the human blood-brain barrier. For 
example, human cerebral microvessels show absence of glucuronidation, low NADPH CYP 
reductase activity, high GST activity, and pronounced epoxide hydrolase activity (Ghersi-
Egea et al., 1993). Understanding metabolising enzymes, specifically at the human blood-
brain barrier with respect to their physiological function, regulation in health and disease, 
and interplay with efflux transporters will allow assessing their impact on drug delivery to 
the brain, particularly in epilepsy. 
3.3 Blood-brain barrier leakage in epilepsy 
Seizures are accompanied by impaired blood-brain barrier integrity. This has been observed 
before, during and after seizures in both experimentally induced seizures in animals as well 
as in epileptic patients (Cornford & Oldendorf, 1986; Horowitz et al., 1992; Mihaly & 
Bozoky, 1984; Nitsch & Klatzo, 1983; Padou et al., 1995). As a consequence, impaired blood-
brain barrier integrity causes transient barrier leakage, which allows entry of blood borne 
molecules into the brain (Ndode-Ekane et al., 2010; Seiffert et al., 2004; Sokrab et al., 1989; 
Van Vliet et al., 2007). It has been shown that seizure duration correlates with reduced 
barrier function (Cornford & Oldendorf, 1986), and it has been demonstrated that increased 
blood-brain barrier permeability in epilepsy is limited to anatomically specific brain regions 
(Bradbury, 1979; Cornford et al., 1998; Nitsch & Klatzo, 1983; Oztas & Sandalci, 1984). 
Interestingly, brain regions with increased barrier permeability are often anatomically 
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congruent with the brain regions that are implicated in the development and propagation of 
seizures. Consistent with this observation, extravasation of blood components into the brain 
correlates with increased excitability, occurrence of seizures, and epilepsy progression 
(Friedman et al., 2009; Marchi et al., 2007; Ndode-Ekane et al., 2010; Oby & Janigro, 2006; 
Seiffert et al., 2004; Tomkins et al., 2008; Van Vliet et al., 2007). 
Cause of Blood-Brain Barrier Leakage by Seizures. Studies conducted over the last 3 
decades indicate that possibly 3 mechanisms could be involved in causing blood-brain 
barrier leakage in epilepsy: blood pressure, pinocytosis, and seizure-induced inflammation. 
Blood Pressure 
The first studies conducted in the 1970s showed that arterial blood pressure is involved in 
seizure-associated blood-brain barrier leakage (Nitsch & Klatzo, 1983). Several studies 
unequivocally demonstrated that hypertension has detrimental effects on blood-brain 
barrier integrity and contributes to barrier leakage (Cornford & Oldendorf, 1986; Lee & 
Olszewski, 1961; Petito et al., 1977; Westergaard, 1980). Johansson summarized three factors 
responsible for increased blood-brain barrier permeability: (1) maximal arterial blood 
pressure, (2) duration of maximal arterial blood pressure, and (3) total increase in blood 
pressure (Johansson, 1981). The detailed mechanism through which increased blood 
pressure contributes to barrier leakage is unclear, but a working hypothesis postulates the 
following (Petito et al., 1977): Neuronal hyperactivity (seizures) leads to increased 
metabolism, and to an increased nutrient and oxygen demand in the involved brain regions. 
In turn, cerebral blood flow rises and large cerebral arteries dilate, which leads to increased 
blood pressure in brain capillaries, small arteries and veins (Ndode-Ekane et al., 2010), and 
triggers barrier leakage. Consistent with this, extravasation of blood albumin into the brain 
was found specifically in regions with more EEG spiking activity in humans (Cornford et al., 
1998). However, the duration of increased blood pressure is critical and determines the 
severity of barrier leakage. Thus, more severe seizures that are followed by prolonged blood 
pressure elevations result in a higher increase in barrier permeability (Oztas & Kaya, 1991; 
Oztas & Sandalci, 1984). This is also supported by studies where both increased arterial 
blood pressure and subsequently induced barrier leakage were prevented by cervical 
cordotomy (Schaefer et al., 1975; Westergaard et al., 1978). 
Pinocytosis 
It was hypothesized that pinocytosis is involved in transport across the capillary 
endothelium, thus, affecting barrier permeability (Palade, 1961). The pinocytosis rate at the 
blood-brain barrier is low, which contributes to a tight barrier endothelium. However, Petito 
et al. observed that seizure-induced blood-brain barrier leakage correlates with increased 
micropinocytosis (Petito et al., 1977). In an elegant study using intravenous HRP injections 
in adult male rats with seizures, the authors made two important findings: (1) Brain 
capillary vesicles from animals that suffered seizures did contain HRP compared to vesicles 
from control animals that did not contain HRP; (2) the number of HRP-containing vesicles 
was higher directly after seizures (within 30 sec of last seizure (Petito et al., 1977)). From 
these observations the authors concluded that an increased micropinocytosis rate during 
and shortly after seizures increases blood-brain barrier permeability and counteracts barrier 
function. Nitsch and Hubauer confirmed these studies and showed in kainic acid-injected 
rats that blood-brain barrier opening was due to increased transendothelial pinocytosis, 
while tight junctions stayed intact (Nitsch & Hubauer, 1986).  
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Seizure-induced Inflammation 
Another factor causing barrier leakage in epilepsy is seizure-induced inflammation that 
could be enhanced by extravasation of blood-borne components into the brain. It has been 
shown that blood-brain barrier permeability is increased by inflammatory mediators, 
including histamine, substance P, endothelin-1, bradykinin, VEGF, TGFß, IL1ß, TNFǂ, INFǄ, 
PGE2, PGF2a, chemokines, free radicals, and other factors such as metalloproteinases, 
thrombin, amyloid-ß, intracellular calcium, and leukocytes that directly interact with 
endothelial cells (Stamatovic et al., 2008). Only limited information is available on how these 
factors alter the blood-brain barrier but some, e.g., IL1ß and chemokines, seem to exclusively 
affect paracellular permeability (Stamatovic et al., 2008). It is currently unknown if secretion 
of these factors is a direct consequence of epileptic seizures. In addition, depending on 
epilepsy aetiopathology, the composition of the inflammatory “cocktail” and the 
contribution of individual inflammatory mediators to blood-brain barrier damage could 
vary significantly. The effect of inflammation on barrier permeability is context-dependent, 
complex and not well understood. It likely depends on the model, dose, time and location of 
the inflammatory mediators involved. 
One hypothesis that could explain some of the phenomena observed at the blood-brain 
barrier in epilepsy is that seizure-released glutamate activates signalling reducing barrier 
integrity and increasing permeability. Glutamate release occurs during seizures at sites in 
the brain with excessive neuronal activity. On the one hand, high glutamate levels are 
cytotoxic, which contributes to brain damage. On the other hand, subtoxic glutamate levels 
trigger molecular processes such as local release and activation of matrix-degrading 
enzymes that breach integrity (Michaluk & Kaczmarek, 2007; Nishijima et al., 2010). It is 
possible that glutamate-initiated signalling and inflammatory mediators cause barrier 
leakage and breakdown in epilepsy. Such events would allow extravasation of blood-borne 
compounds. Whether this scenario is part of seizures remains to be shown. 
Consequences of Blood-Brain Barrier Leakage in Epilepsy. Epilepsy is often a consequence 
of a prior brain insult (e.g., traumatic brain injury, stroke) and seizures are a symptom of an 
underlying brain disorder (e.g., brain tumour, Alzheimer’s disease, brain inflammation; 
(Marchi et al., 2006; Salazar et al., 1985; Tomkins et al., 2011). Although the factors that are 
involved in the development of epilepsy remain unclear, impaired barrier function is 
common after an initial brain insult and likely contributes to epilepsy pathology. This 
particular topic has recently attracted major interest in the epileptology field. 
It has been shown in patients that brain injury, post-ischemic or vascular inflammation often 
cause seizures and barrier leakage (Stamatovic et al., 2008; Tomkins et al., 2011; Tomkins et 
al., 2008). The blood-brain barrier is also impaired in epileptic patients and in seizure animal 
models, and consequently, it has been postulated that barrier leakage is involved in epilepsy 
aetiology (Friedman et al., 2009; Marchi et al., 2007; Ndode-Ekane et al., 2010; Oby & Janigro, 
2006; Seiffert et al., 2004; Tomkins et al., 2011; Tomkins et al., 2008; Van Vliet et al., 2007). In 
addition, it has been shown that osmotic barrier opening causes seizures (Oby & Janigro, 
2006). However, not all implications of barrier opening have been studied. It is known that 
intra-arterial injection of hyperosmotic mannitol in patients and rodents results in EEG 
changes and induces seizures (Fieschi et al., 1980). In a recent study, Marchi et al (2007) 
observed seizures in patients undergoing osmotic barrier opening for delivering 
chemotherapeutics to treat brain lymphomas. In 25% of patients, seizure onset occurred 
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immediately after barrier opening. Using a pig model, the authors demonstrated that 
seizure occurrence correlated with barrier opening and was neither attributed to the existing 
brain lymphoma nor to chemotherapy (Marchi et al., 2007). 
The molecular and cellular events that are triggered by barrier opening and that result in 
seizures and neuronal hyperactivity are a matter of research. Rigau et al. (2007) 
demonstrated loss of functional tight junctions and immunoglobulin leakage into the brain 
in surgically resected hippopcampal tissue from AED-resistant epilepsy patients (Rigau et 
al., 2007). Additional evidence from rodents and resected epileptogenic human brain tissue 
shows that extravasation of albumin into the brain triggers epileptogenesis (Friedman et al., 
2009; Ivens et al., 2010). It was shown that astrocytes incorporated extravasated albumin, 
which induced proepileptogenic transformations, including reduced expression of 
potassium and aquaporin channels and gap junction proteins, impairment of astrocytic 
glutamate metabolism, and increased release of pro-inflammatory mediators (Friedman et 
al., 2009). All these changes had detrimental effects on seizure threshold and susceptibility 
(Friedman et al., 2009). One could postulate that seizures or other factors that induce barrier 
leakage trigger albumin extravasation with subsequent astrocytic transformation eventually 
causing seizures. Such a scenario implies a pernicious feedback loop where seizures drive 
barrier leakage leading to more seizures. Although this hypothesis is a matter of discussion, 
many epileptologists are convinced that ‘seizures beget seizures’ and that epilepsy has a 
progressive nature (Hauser & Lee, 2002). In this regard, alterations of the blood-brain barrier 
and extravasation of blood-borne compounds could be a critical part of epilepsy pathology 
that could potentially be a target for new therapies. 
4. Conclusions 
Research over the last century demonstrated a key role of the blood-brain barrier in the 
development of epilepsy and AED resistance. Despite the advances that have been made, 
what we currently know about AED resistance is mostly limited to descriptive observations 
rather than understanding of the mechanisms underlying the disease. We know that the 
blood-brain barrier is altered in epilepsy including changes in transporters, metabolic 
enzymes, and tight junctions. We also know that transporters, enzymes and tight junctions 
are affected by and/or contribute to epilepsy pathology. Yet, whether each of these 
molecular players is part of a cause-effect jigsaw puzzle and how each of the pieces fit 
together is unclear. Thus, AED resistance in epilepsy remains an unsolved clinical problem.  
To solve this problem future studies will have to address the mechanism of AED resistance 
at the molecular level taking all aspects into account in a “big picture approach” rather than 
focusing on one single piece of the puzzle. The stimuli of blood-brain barrier transporter, 
enzyme and tight junction regulation in epilepsy will have to be identified and the detailed 
chain of signalling events will have to be unravelled. Such information will provide novel 
targets and therapeutic strategies that hold the promise to advance this research field and 
eventually improve treatment of patients with AED-resistant epilepsy. 
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